Department of Psychiatry & Behavioral Sciences, New York Medical College, Valhalla.
J Clin Psychiatry. 2020 Jan 28;81(2):TV18059BR2C. doi: 10.4088/JCP.TV18059BR2C.
Valbenazine and deutetrabenazine are FDA-approved as treatment for tardive dyskinesia (TD). Both medications are vesicular monoamine transporter type 2 (VMAT2) inhibitors, and both are effective for reducing TD symptoms. Clinicians need to be aware of the adverse effects of valbenazine and deutetrabenazine, as well as other key differences between the two, in order to individualize treatment. Using the Abnormal Involuntary Movement Scale assists clinicians in assessing progress for each patient. Treating TD effectively with these new medications will reduce the burden of the condition for patients.
Valbenazine 和 deutetrabenazine 已获得美国食品药品监督管理局（FDA）批准，用于治疗迟发性运动障碍（TD）。这两种药物都是囊泡单胺转运体 2（VMAT2）抑制剂，均可有效减轻 TD 症状。为了实现个体化治疗，临床医生需要了解 valbenazine 和 deutetrabenazine 的不良反应，以及两者之间的其他关键差异。使用异常不自主运动量表（Abnormal Involuntary Movement Scale）可帮助临床医生评估每位患者的治疗进展。使用这些新药物有效治疗 TD 可减轻患者的疾病负担。
